TaiGen Starts China Trial of Novel Chemotherapy Sensitizer

TaiGen Biotechnology of Taiwan has started a China clinical trial of burixafor, the company's novel stem cell mobilizer, which will be tested as a chemotherapy sensitizer. The Phase I/II trial will study burixafor in combination with two chemotherapy agents, fludaragine and cytarabine, in patients with relapsed or refractory acute myeloid leukemia. The drug has already completed a Phase IIa trial in the US. More details.... Stock Symbol: (TWO: 4157) Share this with colleagues: // //